SCHEDULE: Invesco Ltd. Discloses BioLife Solutions Stake

Invesco Ltd. has filed a Schedule 13G, reporting beneficial ownership of 4.9% of BioLife Solutions Inc. common stock as of March 31, 2026.

Summary

• Invesco Ltd. has filed an amendment to its Schedule 13G, indicating its beneficial ownership of BioLife Solutions Inc. common stock.
• As of March 31, 2026, Invesco Ltd. beneficially owns 2,348,532 shares of BioLife Solutions Inc. common stock.
• This represents 4.9% of the total class of securities.
• Invesco Ltd. holds sole voting power over 2,113,765 shares and sole dispositive power over 2,348,532 shares.
• The filing is made by Invesco Ltd. as a parent holding company for its investment advisers, Invesco Advisers, Inc. and Invesco Capital Management LLC.
• The shares are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of ownership by an institutional investor and does not contain operational or financial performance data for BioLife Solutions Inc.

Positives

• Invesco Ltd. maintains a significant stake in BioLife Solutions Inc., indicating confidence from a major institutional investor.
• The ownership percentage of 4.9% is substantial and suggests a notable investment position.

Risks

• The filing does not explicitly detail risks associated with BioLife Solutions Inc. itself, but rather focuses on Invesco's ownership status.
• Potential future changes in Invesco's ownership could impact BioLife Solutions' stock.

Future Outlook

The filing does not contain forward-looking statements or guidance from BioLife Solutions Inc. It pertains to Invesco Ltd.'s ownership disclosure.

Management Comments

• "Invesco Ltd., in its capacity as a parent holding company to its investment advisers, may be deemed to beneficially own 2,348,532 shares of the Issuer which are held of record by clients of Invesco Ltd."
• "The shareholders of the Fund have the right to receive or the power to direct the receipt of dividends and proceeds from the sale of securities listed above."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors crossing certain ownership thresholds. Invesco's filing indicates continued or established investment in the life sciences sector, specifically within companies like BioLife Solutions that support cell and gene therapy markets.

Stakeholder Impact

• Shareholders of BioLife Solutions Inc. may view Invesco's continued significant stake as a positive indicator of institutional support.
• Potential investors may use this filing to understand the institutional ownership landscape of BioLife Solutions Inc.

Next Steps

• Invesco Ltd. will continue to hold its shares in BioLife Solutions Inc. in the ordinary course of business.
• BioLife Solutions Inc. will continue its operations as disclosed in its other filings.

Key Dates

Keywords

Schedule 13G, Invesco Ltd., BioLife Solutions Inc., Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Investment Management, Bermuda, Atlanta